Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773129 | 0.90 | HTR6 (0.58) | L3MBTL1PTGDR2HTR6HTTRAPGEF4 | |
| SCHEMBL13302164 | 0.87 | L3MBTL1 (0.59) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E | |
| SCHEMBL28523210 | 0.86 | L3MBTL1 (0.58) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E | |
| SCHEMBL12657360 | 0.86 | L3MBTL1 (0.58) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E | |
| SCHEMBL29605109 | 0.86 | L3MBTL1 (0.58) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E | |
| SCHEMBL1668563 | 0.86 | L3MBTL1 (0.58) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E | |
| SCHEMBL257136 | 0.85 | KDM4E (0.64) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E | |
| SCHEMBL28325459 | 0.85 | HTR6 (0.57) | L3MBTL1PTGDR2HTR6KDM4EUBE2N | |
| SCHEMBL2984205 | 0.84 | L3MBTL1 (0.55) | L3MBTL1PTGDR2HTR6KDM4EUBE2N | |
| SCHEMBL2447588 | 0.84 | L3MBTL1 (0.55) | L3MBTL1PTGDR2HTR6HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090614-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-04-09 | — | — | US | disclosed |
| US-8946425-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-8796453-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130303764-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-14 | — | — | US | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | L3MBTL1 4557/4885PTGDR2 803/4885HTR6 2043/4885 |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885PTGDR2 1275/4885HTR6 2188/4885 |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885PTGDR2 1275/4885HTR6 2188/4885 |
| US-20130303764-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885PTGDR2 1275/4885HTR6 2188/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | L3MBTL1 4695/4885PTGDR2 1583/4885HTR6 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.